Q-omics provides the consensus-scored C9orf116 profile across patient tissues and cancer cell-line models. C9orf116 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, C9orf116 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, C9orf116 RNA expression shows 17,247 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KICH, and TGCT as cancer lineages where C9orf116 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf116 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf116 survival associations across molecular data types. C9orf116 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf116 RNA expression–survival associations across cancer types. High C9orf116 expression shows unfavorable associations in UCS and UVM, but favorable associations in KIRP, UCEC, READ and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for C9orf116 RNA expression.
This table summarizes C9orf116 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for C9orf116. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf116 shows lower tumor expression in KICH and THCA and higher tumor expression in BLCA, COAD, KIRC and KIRP. The KICH box plot shows higher C9orf116 RNA expression in normal versus tumor tissue (log2 FC = −1.980, t-test p < 0.001).
This table shows molecular features associated with C9orf116 in patient tissues and cancer cell lines. In patient samples, C9orf116 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C9orf116 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BONE.
